2024
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes D, Frey A, Prsic E, Tran T, Clune J, Sznol M, Kluger H, Forman H, Becher R, Olino K, Khan S. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. JAMA Oncology 2024, 10: 342-351. PMID: 38175659, PMCID: PMC10767643, DOI: 10.1001/jamaoncol.2023.6025.Peer-Reviewed Original ResearchNon-small cell lung cancerEnd of lifeMonth of deathImmunotherapy initiationCohort studyMAIN OUTCOMEStage IV non-small cell lung cancerCharlson-Deyo comorbidity indexHigh metastatic burdenInitiation of immunotherapyNational prescribing patternsRisk-adjusted patientsImmune checkpoint inhibitorsRetrospective cohort studyStage IV melanomaPercentage of patientsHigh-volume centersLocation of metastasesLow-volume centersOdds of deathCell lung cancerNational Clinical DatabaseLow-volume facilitiesDrug Administration approvalCheckpoint inhibitors
2023
Role of colectomy in the management of appendiceal tumors: a retrospective cohort study
Marks V, Kerekes D, Butensky S, Ahuja N, Johnson C, Turaga K, Khan S. Role of colectomy in the management of appendiceal tumors: a retrospective cohort study. BMC Gastroenterology 2023, 23: 398. PMID: 37978348, PMCID: PMC10655451, DOI: 10.1186/s12876-023-03019-4.Peer-Reviewed Original ResearchConceptsGoblet cell adenocarcinomaNon-mucinous adenocarcinomaRight hemicolectomyStage 2 diseaseNeuroendocrine neoplasmsTumor typesAppendiceal tumorsMucinous adenocarcinomaAppendiceal goblet cell adenocarcinomaRole of colectomyNational Cancer DatabasePostoperative hospital stayRetrospective cohort studyRisk-adjusted analysisRange of histologiesDifferent tumor typesConclusionsMost patientsHospital stayUnplanned readmissionCohort studySurgical treatmentHistologic typeSurgical outcomesCell adenocarcinomaCancer DatabaseSurgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United States
Kerekes D, Frey A, Bakkila B, Kunstman J, Khan S. Surgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United States. Journal Of Surgical Oncology 2023, 128: 790-802. PMID: 37435780, DOI: 10.1002/jso.27392.Peer-Reviewed Original ResearchConceptsGastroenteropancreatic neuroendocrine carcinomasGEP-NECSingle-site surgeryOverall survivalSurgical treatmentNeuroendocrine carcinomaMortality reductionSite surgeryPrimary siteNational Cancer DatabaseRetrospective cohort studyPrimary tumor typeSurgical resectionCohort studyAggressive diseaseSurgical interventionSurvival outcomesTreatment optionsCancer DatabaseSurgeryPatientsTumor typesNECStrongest predictorCarcinomaHepatopancreatobiliary malignancies: time to treatment matters
Kerekes D, Frey A, Bakkila B, Johnson C, Becher R, Billingsley K, Khan S. Hepatopancreatobiliary malignancies: time to treatment matters. Journal Of Gastrointestinal Oncology 2023, 0: 0-0. PMID: 37201090, PMCID: PMC10186552, DOI: 10.21037/jgo-22-1067.Peer-Reviewed Original ResearchTreatment initiationStage IHPB cancersStage I pancreatic cancerExtrahepatic bile duct cancerKaplan-Meier survival analysisHPB cancer patientsNational Cancer DatabaseRetrospective cohort studyBile duct cancerMedian treatment initiationHepatopancreatobiliary cancersMedian survivalCohort studyDuct cancerOverall survivalHispanic patientsEHBD cancerOncologic careBile ductCox regressionBlack raceCancer patientsDefinitive carePancreatic cancer